{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:29:44Z","timestamp":1771334984368,"version":"3.50.1"},"reference-count":58,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T00:00:00Z","timestamp":1657411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The serum free light-chain (FLC) ratio is a sensitive tool for the differential diagnosis of plasma cell disorders and is biomarker of multiple myeloma (MM) progression from premalignant conditions. Here, we investigate the potential role of FLC ratio at diagnosis in identifying early renal damage in MM patients and other correlations with clinical, laboratory, and molecular findings. A total of 34 MM patients who had undergone autologous stem cell transplantation were included in this retrospective case series study, and FLC quantification was performed with nephelometric assays. In our study, sFLC ratio was significantly associated with light-chain MM and \u03b2-2 microglobulin levels, likely indicating a high disease burden at diagnosis, especially in patients without heavy chain M-protein at serum electrophoresis. Moreover, the sFLC ratio was inversely correlated with glomerular filtration rate, possibly identifying early renal damage in MM patients. Our preliminary results confirm the importance of early sFLC evaluation, especially in patients with the light-chain MM type and low disease burden, to minimize the risk of late renal failure.<\/jats:p>","DOI":"10.3390\/biomedicines10071657","type":"journal-article","created":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T21:19:28Z","timestamp":1657487968000},"page":"1657","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2590-0529","authenticated-orcid":false,"given":"Danilo","family":"De Novellis","sequence":"first","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Fontana","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Carobene","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idalucia","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carmen","family":"Martorelli","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mettivier","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Guariglia","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Luponio","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immacolata","family":"Ruggiero","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"D\u2019Addona","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Di Leo","sequence":"additional","affiliation":[{"name":"Clinical Pathology and Biochemistry Unit, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-6848","authenticated-orcid":false,"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"},{"name":"Department of Medicine, Surgery, and Dentistry, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5861-8984","authenticated-orcid":false,"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[{"name":"Hematology and Transplant Center, University Hospital \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, 84131 Salerno, Italy"},{"name":"Department of Medicine, Surgery, and Dentistry, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.5852","article-title":"Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs","volume":"256","author":"Saltarella","year":"2022","journal-title":"J. Pathol."},{"key":"ref_2","first-page":"999","article-title":"Multiple myeloma: 2014 Update on diagnosis; risk-stratification; and management","volume":"89","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Handa, H., Murakami, Y., Ishihara, R., Kimura-Masuda, K., and Masuda, Y. (2019). The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma. Cancers, 11.","DOI":"10.3390\/cancers11111738"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-019-0267-8","article-title":"Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma","volume":"10","author":"Schieferdecker","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/leu.2008.171","article-title":"Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: Proposed incorporation into the international staging system","volume":"22","author":"Snozek","year":"2008","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"82268","DOI":"10.18632\/oncotarget.19391","article-title":"Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3324\/haematol.2013.083592","article-title":"Multiple myeloma: So much progress; but so many unsolved questions","volume":"98","author":"Moreau","year":"2013","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.3324\/haematol.2019.224360","article-title":"Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels","volume":"105","author":"Heaney","year":"2020","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1080\/00365513.2016.1210337","article-title":"Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions","volume":"245","author":"Milani","year":"2016","journal-title":"Scand. J. Clin. Lab. Investig. Suppl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ccr3.2636","article-title":"Serum free light chains and multiple myeloma: Is it time to extend their application?","volume":"8","author":"Markovic","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.25117","article-title":"Multiple myeloma: 2018 update on diagnosis; risk-stratification; and management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"World Medical Association (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310, 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"GIMEMA (Gruppo Italiano Malattie Ematologiche dell\u2019Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1373\/clinchem.2004.046870","article-title":"Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice","volume":"51","author":"Katzmann","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1515\/CCLM.2011.624","article-title":"N Latex FLC\u2014New monoclonal high-performance assays for the determination of free light chain kappa and lambda","volume":"49","author":"Velthuis","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lopez-Anglada, L., Cueto-Felgueroso, C., Rosi\u00f1ol, L., Oriol, A., Teruel, A.I., Lopez de la Guia, A., Bengoechea, E., Palomera, L., de Arriba, F., and Hernandez, J.M. (2018). GEM (Grupo Espa\u00f1ol de MM)\/PETHEMA (Programa para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas) Cooperative Study Group. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA\/GEM phase III clinical trials. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203392"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Klein, E.M., Tichy, D., Salwender, H.J., Mai, E.K., Duerig, J., Weisel, K.C., Benner, A., Bertsch, U., Akhavanpoor, M., and Besemer, B. (2021). Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers, 13.","DOI":"10.3390\/cancers13194856"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.beha.2005.01.013","article-title":"Renal, hematologic and infectious complications in multiple myeloma","volume":"18","year":"2005","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ccc.2015.06.001","article-title":"Diagnostic Criteria for Acute Kidney Injury: Present and Future","volume":"31","author":"Kellum","year":"2015","journal-title":"Crit. Care Clin."},{"key":"ref_33","first-page":"776","article-title":"Chronic Kidney Disease: Detection and Evaluation","volume":"96","author":"Gaitonde","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yadav, P., Cockwell, P., Cook, M., Pinney, J., Giles, H., Aung, Y.S., Cairns, D., Owen, R.G., Davies, F.E., and Jackson, G.H. (2018). Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0962-x"},{"key":"ref_35","first-page":"5380","article-title":"Normalization of the Serum Free Light Chain Ratio in Patients with Intact Immunoglobulin Multiple Myeloma Who Achieve Less Than Complete Response","volume":"130","author":"Abe","year":"2017","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3324\/haematol.10759","article-title":"Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study","volume":"109","author":"Kaufman","year":"2007","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3324\/haematol.2021.279229","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis","volume":"107","author":"Capra","year":"2022","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2215\/CJN.06100616","article-title":"Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma","volume":"12","author":"Wanchoo","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fmed.2017.00073","article-title":"Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases","volume":"4","author":"Argyropoulos","year":"2017","journal-title":"Front. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.24959","article-title":"Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma","volume":"116","author":"Rossi","year":"2010","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Mynott","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/bjh.14753","article-title":"Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests","volume":"178","author":"Heaney","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1182\/bloodadvances.2019001099","article-title":"Utility of serum free light chain ratio in response definition in patients with multiple myeloma","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.14081","article-title":"Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma","volume":"174","author":"Abbi","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1182\/blood-2013-12-542662","article-title":"Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome","volume":"123","author":"Brioli","year":"2014","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3109\/10428194.2015.1124994","article-title":"Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens","volume":"57","author":"Tacchetti","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4812637","DOI":"10.1155\/2017\/4812637","article-title":"The Evolution of Prognostic Factors in Multiple Myeloma","volume":"2017","author":"Hanbali","year":"2017","journal-title":"Adv. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: Bringing the bench to the bedside","volume":"12","author":"Mailankody","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/bjh.17972","article-title":"Multiparameter flow cytometry in plasma cell disorders: When in doubt; go with the flow","volume":"196","author":"Boyle","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3324\/haematol.2010.031872","article-title":"CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features","volume":"96","author":"Paiva","year":"2011","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2017.320","article-title":"Prognostic value of antigen expression in multiple myeloma: A PETHEMA\/GEM study on 1265 patients enrolled in four consecutive clinical trials","volume":"32","author":"Arana","year":"2018","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): Consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin. Proc."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1657\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:47:28Z","timestamp":1760140048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,10]]},"references-count":58,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071657"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071657","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,10]]}}}